Q3 2022 Results
Company overview
Financial performance
Financial review
2022 priorities
Appendix
Innovation: Pipeline overview
Innovation: Clinical trials
Novartis pipeline in Phase 3
References
Abbreviations
9 lead indications
Lead indication
Mechanism
BCR-ABL inhibitor
Thrombopoietin receptor
(TPO-R) agonist
CFB inhibitor
Indication(s)
Chronic myeloid leukemia, 1st line
Radiation sickness syndrome
Paroxysmal nocturnal haemoglobinuria
Atypical haemolytic uraemic syndrome
Myelodysplastic syndrome
2L Diffuse large B-cell lymphoma²)
Solid Tumors
Code
AAA617
Name
Mechanism
Indication(s)
Hematology
Code
Name
PluvictoⓇ
Radioligand therapy target PSMA mCRPC, pre-taxane
ABL001
AAA6011)
Lutathera®
Metastatic hormone sensitive prostate cancer (mHSPC)
Radioligand therapy target SSTR Gastroenteropancreatic neuroendocrine tumors, 1st line in G2/3
tumors (GEP-NET 1L G3)
ETB115
ScemblixⓇ
PromactaⓇ
LNP023
iptacopan
BYL719
JDQ443
PiqrayⓇ
JDQ443
PI3Ka inhibitor
HER2+ adv BC
Triple negative breast cancer Ovarian cancer
KRAS inhibitor
LEE011
Kisqali®
NIS793
NIS793
CDK4/6 Inhibitor
TGFB1 inhibitor
2/3L Non-small cell lung cancer
HR+/HER2- BC (adj)
MBG453
YTB323
sabatolimab
YTB323
TIM3 antagonist
CD19 CAR-T
1L Metastatic pancreatic ductal adenocarcinoma
VDT482
Tislelizumab
PD1 inhibitor
1L Nasopharyngeal Carcinoma
1L ESCC
Adj/Neo adj. NSCLC
1L Gastric cancer
Cardiovascular
1L Hepatocellular Carcinoma
Localized ESCC
Code
Name
1L Urothelial Cell Carcinoma
1L Small Cell Lung Cancer
KJX839 LeqvioⓇ
LNP023 iptacopan
CFB inhibitor
Immunology
Code
Name
AIN457
Cosentyx®
Mechanism
IL17A inhibitor
BTK inhibitor
BAFF-R inhibitor
Indication(s)
Lupus Nephritis
Psoriatic arthritis (IV formulation)
Axial SpA (IV formulation)
Giant cell arteritis
Food allergy
Chronic spontaneous urticaria
Food allergy
Sjögren's
Lupus Nephritis
IGE025
LOU064
Xolair
IgE inhibitor
remibrutinib
QGE031
ligelizumab
IgE inhibitor
VAY736 ianalumab
Neuroscience
Code
Name
AMG334 AimovigⓇ
BAF312 Mayzent®
LOU064 remibrutinib
OAV101 AVXS-101
OMB157 KesimptaⓇ
Mechanism
CGRPR antagonist
S1P1,5 receptor modulator
BTK inhibitor
Indication(s)
Migraine, pediatrics
Multiple sclerosis, pediatrics
Multiple sclerosis
SMN1 gene replacement therapy SMA IT administration
CD20 Antagonist
Multiple sclerosis, pediatrics
1. 177 Lu-dotatate in US. 2. Ph3 to be initiated pending strategy update.
39 Investor Relations | Q3 2022 Results
Mechanism
siRNA (regulation of LDL-C)
TQJ230
Pelacarsen
ASO targeting Lp(a)
Indication(s)
CVRR-LDLC
IgA nephropathy
Hyperlipidemia, pediatrics
C3 glomerulopathy
Secondary prevention of cardiovascular events in patients with
elevated levels of lipoprotein (a) (CVRR-Lp(a))
Others
Code
Global Health
COA566 Coartem®
Ophthalmology
RTH258 BeovuⓇ
Name
Mechanism
VEGF inhibitor
Biosimilars
Code
Name
GP2411 denosumab
SOK583 aflibercept
Mechanism
anti RANKL mAb
VEGF inhibitor
Indication(s)
Malaria, uncomplicated (<5kg patients)
Diabetic retinopathy
Indication(s)
Osteoporosis (same as originator)
Ophthalmology indication (as originator)
NOVARTIS | Reimagining MedicineView entire presentation